SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report, dated July 7, 2025, details a material definitive agreement entered into by BioSig Technologies, Inc. (the "Company"). The filing discloses a significant capital raise and financing arrangement with YA II PN, LTD. ("Yorkville"). The Company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol BSGM.
Key Financial Metrics and Transaction Terms
- Convertible Debentures: The Company agreed to sell senior secured convertible debentures with an aggregate principal amount of $100,000,000.
- First Convertible Debenture: $75,000,000 principal.
- Second Convertible Debenture: $25,000,000 principal.
- Purchase Price: 96.0% of the principal amount for each debenture.
- Interest Rate: 4.00% per annum, increasing to 18.00% per annum upon an event of default.
- Maturity: 24 months from the issuance of the First Convertible Debenture.
- Prepayment: Company may prepay with a 10% premium on the principal amount.
- Standby Equity Purchase Agreement (SEPA): The Company has the right to sell up to $1,000,000,000 of common stock to Yorkville over a 36-month period.
- Pricing: 97% of the lowest volume-weighted average price (VWAP) during the three trading days following an advance notice.
- Commitment Fee: 1.0% of the commitment amount, payable in cash or stock.
- Security: Obligations are secured by a first-priority security interest in substantially all existing and future assets of the Company and subsidiaries (including Streamex), excluding $50,000,000 of proceeds reserved for working capital and gold tokenization.
- Conversion Terms: Conversion price is the lower of a fixed price (125% of VWAP prior to closing, subject to reset) or 97% of the lowest daily VWAP in the three days preceding conversion, subject to a floor price of 20% of the Nasdaq Official Closing Price.
Material Changes and Conditions
The transaction represents a material change in the Company's capital structure and debt obligations. Key conditions include:
- Closing Conditions: The First Debenture requires stockholder approval for the issuance of debentures and conversion shares. The Second Debenture requires the effectiveness of a Resale Registration Statement with the SEC.
- Ownership Caps: Conversion is limited to prevent the Investor from beneficially owning more than 4.99% of outstanding common stock (Beneficial Ownership Limit) or 19.99% of outstanding common stock (Exchange Cap), unless stockholder approval is obtained.
- Lock-Up: Directors, officers, and certain stockholders are subject to an 180-day lock-up period on their holdings following the issuance of the First Debenture.
Outlook, Risks, and Management Commentary
The Company intends to use the proceeds for general working capital purposes, including gold tokenization. The filing highlights several risks and contingencies:
- Dilution Risk: The convertible nature of the debentures and the SEPA could result in significant dilution to existing shareholders, subject to the 19.99% Exchange Cap.
- Default Risk: Interest rates jump to 18.00% upon an event of default, and the holder may foreclose on collateral securing the obligations.
- Regulatory Risk: The Second Debenture and full utilization of the SEPA are contingent on SEC registration effectiveness and stockholder approvals.
- Unusual Items: The transaction includes a "downward only reset" on the conversion price and a floor price mechanism, which are specific to this financing structure.
Investor Verification Checklist
- Verify the status of the required stockholder approval for the issuance of the First Convertible Debenture and Conversion Shares.
- Confirm the effectiveness of the Resale Registration Statement required for the Second Convertible Debenture and SEPA.
- Review the specific terms of the "floor price" and "downward only reset" mechanisms in the conversion formula to assess potential dilution scenarios.
- Assess the impact of the 180-day lock-up agreement on the liquidity of shares held by insiders.
- Examine the collateral agreement to understand the extent of assets pledged, specifically regarding the exclusion of $50,000,000 for working capital.